Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Credit NIAID-RML
Highlighted Sections
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Vilobelimab
A new section discusses the clinical data on the use of the anti-C5a monoclonal antibody vilobelimab for the treatment of COVID-19.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The section has been updated to reflect the recent FDA approval of ritonavir-boosted nirmatrelvir.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Immunocompromised
The Panel provides treatment options for patients who are immunocompromised and have prolonged, symptomatic COVID-19 with evidence of ongoing SARS-CoV-2 replication.
Hospitalized Children: Therapeutic Management of MIS-C
The recommended therapy for MIS-C is a glucocorticoid plus IVIG. Recent data support the use of glucocorticoid monotherapy, but only if IVIG is not available or contraindicated.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Vilobelimab
A new section discusses the clinical data on the use of the anti-C5a monoclonal antibody vilobelimab for the treatment of COVID-19.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The section has been updated to reflect the recent FDA approval of ritonavir-boosted nirmatrelvir.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Immunocompromised
The Panel provides treatment options for patients who are immunocompromised and have prolonged, symptomatic COVID-19 with evidence of ongoing SARS-CoV-2 replication.
Hospitalized Children: Therapeutic Management of MIS-C
The recommended therapy for MIS-C is a glucocorticoid plus IVIG. Recent data support the use of glucocorticoid monotherapy, but only if IVIG is not available or contraindicated.
Clinical Management of Adults Summary
This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.
Vilobelimab
A new section discusses the clinical data on the use of the anti-C5a monoclonal antibody vilobelimab for the treatment of COVID-19.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
The section has been updated to reflect the recent FDA approval of ritonavir-boosted nirmatrelvir.
Clinical Management of Children Summary
The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.
Immunocompromised
The Panel provides treatment options for patients who are immunocompromised and have prolonged, symptomatic COVID-19 with evidence of ongoing SARS-CoV-2 replication.
Hospitalized Children: Therapeutic Management of MIS-C
The recommended therapy for MIS-C is a glucocorticoid plus IVIG. Recent data support the use of glucocorticoid monotherapy, but only if IVIG is not available or contraindicated.